parkinson, Parkinson's research notebook

Six readers

reader	found	score
genetics Open Targets	no genetic evidence; overall 0.28 from other evidence	0.00
cell type Human Protein Atlas	cell type enhanced, including oligodendrocytes; strongest in neutrophils	0.75
chemistry Open Targets	compounds already reach it: semagacestat, avagacestat, tarenflurbil +4	0.90
trials ClinicalTrials.gov	2 Parkinson's trials, 1 stopped	0.60
literature PubMed	130 Parkinson's papers of 1,744	0.36
pathways Reactome	14 pathways; mostly protein handling	0.90

No case: the score is under the bar. Receipt 1413

receipt 1421: PSEN1 in dopamine neurons, braak

power: full sample -0.03 (p 0.894, n 18), 95% CI -0.49 to +0.44. the interval is wide: not enough donors to tell.
confounder: adjusted for sex: -0.07 (p 0.794, n 18). does not hold up.
composition: dopamine neurons share of nuclei vs axis +0.05 (p 0.854); controlling for it: -0.04 (p 0.881, n 18). could be the mix.
skeptic: leave-one-out range -0.16 to +0.08, sign flips 5; without severely affected donors -0.03 (p 0.894, n 18). fragile.
cell type: no other cell group does better.
axis: no measure beats "tracks Braak Lewy-body stage" for PSEN1 in dopamine neurons.

case closed: nothing better to follow up.

receipt 1420: PSEN1 in oligodendrocytes, braak

power: full sample -0.09 (p 0.722, n 18), 95% CI -0.53 to +0.39. the interval is wide: not enough donors to tell.
confounder: adjusted for sex: -0.12 (p 0.646, n 18). does not hold up.
composition: oligodendrocytes share of nuclei vs axis +0.03 (p 0.915); controlling for it: -0.05 (p 0.847, n 18). could be the mix.
skeptic: leave-one-out range -0.22 to +0.02, sign flips 2; without severely affected donors -0.09 (p 0.722, n 18). fragile.
cell type: no other cell group does better.
axis: no measure beats "tracks Braak Lewy-body stage" for PSEN1 in oligodendrocytes.

case closed: nothing better to follow up.

loading the receipts